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Abstract
Background:  Polycystic ovaries (PCO) and their clinical expression (the polycystic ovary
syndrome [PCOS]) as well as type 2 diabetes mellitus (T2DM) are common medical conditions
linked through insulin resistance. We studied the prevalence of PCO and PCOS in women with
diet and/or oral hypoglycemic treated T2DM and non-diabetic control women.
Design: Prospective study.
Methods:  One hundred and five reproductive age group women with diet and /or oral
hypoglycemic treated T2DM were the subjects of the study. Sixty age-matched non-diabetic
women served as controls. Transabdominal ultrasonographic assessment of the ovaries was used
to diagnose PCO. Clinical, biochemical and hormonal parameters were also noted.
Results: Ultrasonographic prevalence of PCO was higher in women with diabetes than in non-
diabetic subjects (61.0% vs. 36.7%, P < 0.003) whereas that of PCOS was 37.1% in diabetic subjects
and 25% in non-diabetic controls (P > 0.1). Diabetic women with PCO had diabetes of significantly
longer duration than those without PCO (4.19±2.0 versus 2.9±1.6 yrs; p < 0.05). Among both
diabetic and non-diabetic women, those with PCO had significantly higher plasma LH, LH/FSH ratio,
total testosterone and androstenedione levels.
Conclusion: This study demonstrates a higher prevalence of PCO in women with T2DM as
compared to non-diabetic subjects.
Introduction
Polycystic ovary syndrome (PCOS) has, since its first
description by Stein and Leventhal in 1935, become one
of the commonest disorders in women, affecting 5 to 10%
in the reproductive age-group [1-3]. This common medi-
cal condition has brought gynecologists, endocrinolo-
gists, cardiologists, pediatricians, and dermatologists
together [4]. The disorder manifests as obesity, hirsutism,
menstrual disturbances, acne vulgaris, male-pattern bald-
ness, recurrent abortions, infertility, an-ovulation, and
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psychological and psychosexual morbidity [5]. It is an
important cause of hirsutism and of infertility in our pop-
ulation [6,7]. With the advances and refinement in ultra-
sound technology, the presence of polycystic appearance
of ovaries has increasingly been accepted as an essential
part of the diagnosis of this syndrome and ultrasound sug-
gestion of PCO has recently been introduced as one of the
three diagnostic criteria of PCOS in Rotterdam consensus
workshop 2003 [8]. Using the most conservative criteria
for transabdominal studies, such as presence of ≥ 10
peripheral cysts per ovary, each 2–8 mm, and thickened
stroma, some authors have shown that as many as 21–
23% of normal female population have PCO on ultra-
sound [9-11]. Some women with otherwise confirmed
PCOS may have normal sized ovaries on ultrasound and
normal sized ovaries without increased folicllarity don't
preclude the diagnosis in proper clinical settings [12-14].
The pathophysiology of PCOS, one of the commonest
endocrinopathies, is far from clear. A plethora of data
point to insulin resistance (IR) and hyperinsulinemia as
the central factor, a suggestion supported by clinical ben-
efits of insulin sensitizers [3,5,15,16].
T2DM, which accounts for 90–95% of all diabetes melli-
tus, is a common metabolic disorder, characterized by a
combination of IR and insulin secretory defects, occurring
in varying proportions [17]. Both T2DM and PCOS are
now considered to be two metabolically similar but phe-
notypically different expressions of the same syndromic
continuum with IR being the common and pivotal link,
which may be genetically determined [15,18]. Women
with PCOS are also at increased risk for cardiovascular dis-
ease (CVD), given the high prevalence of the metabolic
syndrome among them [19]. Many studies have revealed
an increased prevalence of various abnormalities of glu-
cose tolerance in women with PCOS [3,20,21]. The scar-
city of converse data on the prevalence of PCO among
women with T2DM prompted this study on the preva-
lence of PCO in a cohort of premenopausal women with
insulin naive T2DM.
Subjects and Methods
The study was conducted in the department of Endo-
crinology of Sheri-Kashmir Institute of Medical Sciences
Srinagar Kashmir (India), a tertiary care center. One hun-
dred and sixty five premenopausal (≤ 45 years) women,
from Kashmir region of India, were studied for sono-
graphic suggestion of PCO in addition to recording of
clinical, biochemical and hormonal manifestations of
PCOS. Informed consent was obtained from all subjects
and the institutional review board, that looks in to ethical
aspects of human experimentation approved the study.
Subjects
a. Patient group: This group comprised of 105 non-preg-
nant women with T2DM of at least one year duration
treated with medical nutrition therapy and/or oral
hypoglycemic drugs. Women with current or past history
of insulin treatment, oral contraceptive use, and suspicion
of nephropathy were excluded from the study.
b. Control group: Sixty non-diabetic, healthy pre-meno-
pausal volunteers served as controls.
Methods
Each patient and control received a detailed clinical exam-
ination and underwent a relevant laboratory evaluation.
a. Clinical assessment: The history focused on age, men-
strual pattern, fertility status, duration and treatment of
diabetes (in diabetic women), and other relevant drug his-
tory. Menstrual pattern was characterized as regular
(cycles recurring every 21–35 days), oligommenorrhea
(cycle length over 35 days and under six months), poly-
menorrhea (cycles occurring more frequently than every
21 days), menorrhagia (heavy menstruation requiring
intervention) and amenorrhoea (absence of menstruation
for six months or longer). Fertility status was classified as
fertile (had a previous pregnancy with no subsequent
infertility), infertile (primary or secondary infertility of at
least 1 year duration) and unproven (pregnancy not
attempted).
The physical examination, apart from a general review of
the systems, focused on the assessment of androgen status
(hirsutism, temporal recession of hair, acne, muscle bulk,
clitoromegaly), evidence of IR (acanthosis nigricans), and
anthropometry, (body mass index (BMI), waist circumfer-
ence). Ferriman and Gallwey scoring system was used to
assess hirsutism, [22]. and a score of 7 or more was taken
as significant.
b. Laboratory evaluation. The baseline investigations
included blood counts, chest x-ray, electrocardiogram,
liver and kidney function tests, glucose and lipid (total
cholesterol, HDL, and triglycerides) levels. A pool of three
samples taken 15 minutes apart during early follicular
phase was analyzed for LH, FSH, total testosterone and
androstenedione levels. The blood sample for all investi-
gations were taken in the fasting state in a single visit. The
samples were taken in early follicular phase (day 3 – day
5) in women with regular cycles in all subjects and
controls.
c. Ultrasonography. A specifically trained radiologist,
using Siemens Sonoline Adara with 3.5 MHz convex elec-
tronic probe performed the transabdominal ultrasonogra-
phy. Local socio-cultural constraints precluded a vaginalReproductive Biology and Endocrinology 2005, 3:35 http://www.rbej.com/content/3/1/35
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approach. The diagnosis of PCO was made, if 10 or more
follicles, each 2–8 mm diameter were present in the ovar-
ian periphery, and stroma was echo dense [23]. The ovar-
ian volume was calculated by measuring the diameters in
three dimensions and assuming an ellipsoid shape using
the formula, volume = height × width × depth × π/6.
d. Hormonal assays. All hormone estimations were done
with radioimmunoassay. Total testosterone and andros-
tenedione were measured using commercial kits from
DPC, Los Angeles CA. Serum LH and FSH was assayed by
immunoradiometric assays using kits from Medicorp Inc.,
Montreal, Canada. Sensitivity, specificity, and inter- and
intra-assay coefficients of variation were within the pre-
scribed limit as provided by the manufacturer.
Statistical analysis
SPSS 10.0 package was used for analysis of data. Correla-
tions were done by Pearson's test. Categorical variables
were compared by using Chi-square test, and for continu-
ous variables, 't' test was used for comparing two groups
and one way ANOVA when more than two groups were
involved. Two tailed significance was calculated and a P
value of <0.05 was taken as significant.
Results
The baseline characteristics of diabetic and control
women (Table 1) were comparable except for significantly
higher systolic and diastolic blood pressures in the
former. Table 2 compares the various metabolic and hor-
monal parameters between diabetic and non-diabetic
women. While the mean fasting blood glucose and LDL
levels were significantly higher in diabetic women, the
mean levels of cholesterol, HDL, triglycerides and VLDL
were similar in diabetic and control groups. The diabetic
women had a significantly higher mean ovarian volume
than controls (6.15 ± 1.4 ml vs. 5.66 ± 1.4 ml, P < 0.04).
On ultrasonography, PCO was found in 64 (60.9%) and
22 (36.7%) of diabetic and control women respectively,
giving a significantly higher prevalence in the diabetic
women (P < 0.05). In women with PCO, those with and
without T2DM had comparable mean ovarian volumes
(5.80 ± 1.18 vs. 5.98 ± 1.28 ml; P > 0.5). Among women
with T2DM, those with PCO had a significantly higher
mean ovarian volume than those without PCO (5.80 ±
1.18 vs. 4.13 ± 1.07 ml; P < 0.001).
Table 3 shows clinical features in subjects with and with-
out PCO on ultrasonography in both groups. Overall,
PCO-syndrome (PCOS) was seen in 39 (37.1%) subjects
Table 1: Clinical profile of study subjects
Clinical parameter Patients (n = 105) Controls (n = 60) p
Age (yrs) 36.19 ± 4.37* 34.98 ± 4.60 0.096
SBP (mmHg) 138.95 ± 12.39 132.75 ± 10.17 0.01†
DBP (mmHg) 84.84 ± 7.72 81.13 ± 8.57 0.05†
BMI (kg/m2) 25.42 ± 3.2 25.72 ± 3.2 0.57
W/H ratio 0.94 ± 0.7 0.93 ± 0.6 0.92
* Mean ± SD; †Significant
Table 2: Metabolic and hormonal profile of study subjects
Parameter Patients (n = 105) Controls (n = 60) P
Fasting glucose (mg/dl) 120.61 ± 34.79* 88.07 ± 14.18 0.001†
Total cholesterol (mg/dl) 193.51 ± 47.88 183.63 ± 39.72 0.177
Triglycerides (mg/dl) 193.69 ± 68.80 185.68 ± 70.89 0.478
LDL cholesterol (mg/dl) 128.96 ± 61.9 102.78 ± 40.1 0.004†
HDL cholesterol (mg/dl) 42.52 ± 7.56 43.99 ± 8.92 0.262
VLDL cholesterol (mg/dl) 38.7 ± 13.7 37.1 ± 14.1 0.478
LH (IU/L) 5.91 ± 5.72 4.67 ± 6.44 0.20
LH/FSH 1.01 ± 0.73 0.84 ± 0.66 0.132
Testosterone (ng/ml) 0.29 ± 0.22 0.27 ± 0.14 0.335
Androstendione (ng/ml) 1.87 ± 1.70 1.54 ± 0.64 0.157
* Mean ± SD; †SignificantReproductive Biology and Endocrinology 2005, 3:35 http://www.rbej.com/content/3/1/35
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with T2DM and 15 (25.0%) controls. However, this dif-
ference was not statistically significant (P > 0.1). The
mean duration of diabetes and mean serum LH, testoster-
one, androstenedione, and LH/FSH ratio were signifi-
cantly higher in diabetic women with than in those
without PCO (Tables 3 &4). While non diabetic controls
with and without PCO had comparable age, age at
menarche, diastolic blood pressure, BMI and waist hip
ratios, the former had a significantly higher mean systolic
blood pressure (Table 3). As in the diabetic women, non-
diabetic controls with PCO had higher LH, LH/FSH ratio,
testosterone and androstenedione levels than those with-
out PCO; among both diabetic and non diabetic women,
the blood glucose, and lipid levels were comparable in
those with and without PCO (Table 4). The clinical and
biochemical parameters of diabetic and non-diabetic
women with PCO were comparable (Tables 3 &4). Of 105
diabetic subjects, 55 were overweight-obese (BMI ≥ 25)
whereas of 60 controls, 30 were overweight-obese. Table
5 shows clinical features and frequency of PCO and PCOS
in these obese and non-obese subjects.
Discussion
PCOS and T2DM are common medical conditions and
both are associated with IR and compensatory hyperin-
sulinemia [24]. The clinical and biochemical features of
PCOS are heterogeneous and there is much debate
whether it represents a single or several disorders [2]. In
recent years it has become apparent that PCOS not only is
the most frequent cause of anovulation and hirsutism, but
also is associated with characteristic metabolic distur-
bances that may have implications for long-term health
[2,4]. Recently IR has been clearly documented by many
investigators in PCOS, although the cause of IR is
unknown and its relationship with PCOS as an etiological
agent or an epiphenomenon remains unsettled
[3,15,25,26]. T2DM is a common disorder characterized
by IR and compensatory hyperinsulinemia [17]. An
increased incidence of glucose intolerance and DM has
been reported in women with a history of PCOS com-
pared to controls in long-term studies [3,20,21]. If IR and
hyperinsulinemia have an important role in determining
ovarian morphology, PCO and their clinical expression
can be expected to be more common among women with
T2DM. We compared the prevalence of PCO on ultra-
sound in a defined clinic population of women with
T2DM and in a group of age matched non-diabetic con-
trol women.
In our study 60.95% of the 105 premenopausal women
with T2DM were documented to have PCO compared to
36.66% of the 60 non-diabetic controls. This prevalence
in our study is much higher than the reported prevalence
of 21–23% among normal female population [9-11]. In
previous studies we observed PCOS to be second
common cause of both hirsutism and infertility in our
Table 3: Clinical profile of diabetic patients and controls with and without PCO
Clinical Parameter Diabetic subjects Controls P value (ANOVA)
PCO (n = 64) Non-PCO (n = 41) PCO (n = 22) Non-PCO (n = 38)
Age (years), Mean ± SD 36.8 ± 4.28* 35.2 ± 4.4 34.2 ± 4.5 35.5 ± 4.6 0.000
Duration of DM (y), Mean ± SD 4.19 ± 2.0 2.9 ± 1.6 a -- -- 0.000
Age of menarche (y), Mean ± SD 13.5 ± 0.8 13.50 ± 0.6 13.1 ± 0.8 13.1 ± 0.7 0.015
Menstrual irregularity, 24 (37.5%) 4 (9.8%) 0 0 0.000
Oligomenorrhea 12 (18.8%) 1 (2.4%)
Polymenorrhea 1 (1.6%) 1 (2.4%)
Mennorrhagia 11 (17.2%) 2 (4.9%)
Infertility 4 (6.2%) 0 0 0 0.368
Hirsuitism 9 (14.1%) 0 4 (18.2%) 2 (5.3%) 0.030
Acne 3 (4.7%) 0 1 (4.5%) 1 (2.6%) 0.564
Acanthosis 2 (3.1%) 0 0 0 0.368
History of hypertension 40 (78%) 30 (73%) 0 0 0.000
SBP (mmHg), Mean ± SD 140 ± 12.7 139 ± 12.3 138 ± 9.5 130 ± 9.3 b 0.000
DBP (mmHg), Mean ± SD 85.8 ± 7.8 83.3 ± 7.3 82.1 ± 10.2 80.58 ± 7.5 0.012
BMI (kg/m2), Mean ± SD 25.8 ± 3.1 24.7 ± 3.3 26.36 ± 2.8 25.34 ± 3.3 0.180
Waist to hip ratio, Mean ± SD 0.94 ± 0.6 0.92 ± 0.7 0.94 ± 0.6 0.92 ± 0.6 0.426
Ovarian volume (ml), Mean ± SD 5.80 ± 1.18 4.13 ± 1.07 5.98 ± 1.28 3.89 ± 0.88 0.000
PCOS† 39 (61%) 0 15 (68%) 0 0.000
* on ultrasonography
a: P < 0.05, in the subject group, b: P < 0.05, in control group
† PCOS by Rotterdam ASRM/ESHRE consensus criteriaReproductive Biology and Endocrinology 2005, 3:35 http://www.rbej.com/content/3/1/35
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population [6,7]. Rodin et al reported an overall preva-
lence of 52% of PCO in women of Indian subcontinent
origin living in England [27]. Conn et al studied 38 pre-
menopausal women using the same ultrasonographic
criteria and reported prevalence 82% among women with
T2DM [24]. Not much data are available on the preva-
lence of PCO among diabetic women.
In our study diabetic females with PCO had significantly
higher mean LH, total testosterone and androstenedione
than diabetic females without PCO. Conn and colleagues
found comparable mean levels of LH and testosterone in
diabetic women with and without PCO and significantly
higher levels of androstenedione in the former [24].
Another study, including women with and without diabe-
tes, found significantly higher mean testosterone levels in
women with PCO than in those without [27]. No statisti-
cally significant differences were found between mean
systolic and diastolic blood pressures, BMI, waist hip
ratios, HDL-cholesterol and triglyceride levels in diabetic
women with and without PCO like observations made
earlier by Conn et al [24]. We did not find any difference
in the prevalence of PCO among obese (BMI ≥ 25 kg/m2)
and non-obese (BMI <25 kg/m2) women with T2DM. No
study has compared the prevalence of PCO among obese
and non-obese type 2 diabetic women. As in the patient
group, non-diabetic controls with PCO had significantly
higher mean LH, testosterone and androstenedione levels
and mean ovarian volume than those without PCO; all
clinical and metabolic parameters were comparable
between these two subgroups of non-diabetic controls
except mean systolic blood pressure which was signifi-
Table 4: Showing comparison of metabolic and hormonal profile in diabetic subjects and non-diabetic controls on the basis of presence 
or absence of ultrasonic suggestion of polycystic ovaries (PCO).
Clinical parameter Diabetic subjects Controls P (ANOVA)
PCO (n = 64) Non-PCO (n = 41) PCO (n = 22) Non-PCO (n = 38)
Fasting glucose (mg/dl) 123.8 ± 36.28 115.55 ± 32.0 92.14 ± 12.7 85.71 ± 14.6 0.000
Total cholesterol (mg/dl) 189.4 ± 40.9 199.8 ± 57.0 183.27 ± 37.6 183.87 ± 41.3 0.375
Triglycerides (mg/dl) 194.4 ± 69.9 192.4 ± 67.8 182.27 ± 52.1 187.65 ± 80.2 0.895
HDL cholesterol (mg/dl) 42.0 ± 6.6 43.3 ± 8.8 44.00 ± 11.0 43.99 ± 7.6 0.593
LDL cholesterol (mg/dl) 127.5 ± 55.2 131.1 ± 71.9 97.74 ± 40.7 105.76 ± 40.0 0.033
VLDL cholesterol (mg/dl) 38.8 ± 13.9 38.4 ± 13.5 36.45+10.4 37.53+16.0 0.895
LH (IU/L) 7.51+6.65 3.42 +2.21a 7.93 ± 9.52 2.77 ± 2.17b 0.000
FSH (IU/L) 5.82+2.80 7.23+4.86 5.50 ± 2.3 5.11 ± 2.9 0.039
LH/FSH ratio 1.31 ± 0.78 0.55 ± 0.26a 1.3 ± 0.85 0.5 ± 0.26b 0.000
Testosterone (ng/ml) 37.4 ± 23.0 16.9 ± 7.3a 39.6 ± 13.3 18.8 ± 7.5b 0.000
Androstendione (ng/ml) 2.40 ± 1.9 1.04 ± 0.36a 2.10 ± 0.6 1.21 ± 0.40b 0.000
* Mean ± SD
a: P < 0.05, in the subject group, b: P < 0.05, in control group
Table 5: Clinical features and frequency of PCO/PCOS in obese and non-obese subjects
Characteristic Diabetic cases Controls P value
Obese (n = 55) Non-obese (n = 50) Obese (n = 30) Non-obese (n = 30)
Menstrual irregularity
Oligomenorrhea 9 (16.4%) 4 (8.0%) 0 0 0.014
Polymenorrhea 2 (3.6%) 0 0 0 0.256
Mennorrhagia 9 (16.4%) 4 (8.0%) 0 0 0.014
Hirsutism 7 (12.7%) 2 (4.0%) 2 (6.7%) 4 (13.3%) 0.346
Acne 2 (3.6%) 1 (2.0%) 1 (3.3%) 1 (3.3%) 0.966
Acanthosis nigricans 2 (3.6%) 0 0 0 0.256
PCO 34 (61.8%) 30 (60.0%) 14 (46.7%) 8 (26.7%) 0.009
PCOS 22 (40.0%) 17 (34.0%) 10 (33.3%) 8 (16.7%) 0.181Reproductive Biology and Endocrinology 2005, 3:35 http://www.rbej.com/content/3/1/35
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cantly more among controls with than without PCO
(138.1 vs. 129.6 mmHg).
We found a significantly higher mean LDL levels in: a)
diabetic women than non-diabetic women (128 mg/dl vs.
102 mg/dl), b) women with PCO and T2DM than women
with PCO and without T2DM (127 mg/dl vs. 97 mg/dl)
and c) obese women with PCO and T2DM than obese
women with PCO but without T2DM (139 mg/dl vs. 87
mg/dl). This likely reflects the effect of diabetes on plasma
lipids. An earlier study by Rodin found no difference in
respect to LDL, HDL, triglycerides or total cholesterol in
women of Indian sub continental ancestry with and with-
out PCO [27]. Comparing women with PCO from the dia-
betic and control groups, a significant difference was
found in the mean age of women from these two groups
(36.83 vs. 34.18 years; P < 0.02). The mean LDL level in
women with T2DM and PCO was significantly higher
than in controls with PCO (127 vs. 97 mg/dl; P < 0.03);
other parameters including diastolic blood pressure, BMI,
waist hip ratio, cholesterol, triglycerides, HDL, VLDL, LH,
testosterone and androstenedione and ovarian volume
were comparable between women with PCO and with or
without T2DM.
The significantly longer duration of diabetes among dia-
betic patients with PCO compared to those without PCO
in our study probably reflects longer duration of insulin
resistance/hyperinsulinemia in the former. IR is consid-
ered central to the pathogenesis of PCOS and south Asian
women with PCOS have been reported to be more insulin
resistant, seek treatment at a younger age and have more
severe symptoms than Caucasians [28]. Hyperinsuline-
mia augments androgen production in PCOS directly by
augmenting LH activity through stimulation of ovarian
receptors of insulin and insulin-like growth factors or
indirectly, by enhancing the amplitude of serum LH
pulses [5]. Furthermore, hyperinsulinemia decreases
SHBG levels increasing the amount of free testosterone
available to act on target organs [24]. Legro and colleagues
reported that 50–70% of women with PCOS have IR
which probably contributes to hyperandrogenism under-
lying the signs and symptoms of PCOS [29]. While IR is a
common feature of both PCOS and T2DM, persistent
reproductive dysfunction appears to be limited to the
former raising the possibility that IR in the ovary itself
may confer this susceptibility. The exact role and mecha-
nism(s) thereof IR and hyperinsulinemia are far from
fully understood. While Conn et al,24 found fasting insu-
lin levels in diabetic women with and without PCO to be
comparable, Rodin et al [27]. observed in a more geneti-
cally homogenous group of Asian women, that those with
both PCO and T2DM were more insulin resistant than
those with diabetes alone.
In conclusion our study demonstrates a higher prevalence
of PCO and its clinical expressions in women with T2DM
compared to non-diabetics. The precise role of hyperin-
sulinemia in development and expression of PCO
remains largely unresolved and needs elucidation.
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